Docstoc

Drug Discovery in Rare Diseases

Document Sample
Drug Discovery in Rare Diseases Powered By Docstoc
					Drug Discovery in Rare Diseases
Report Details:
Published: August 2012
No. of Pages: 108
Price: Single User License: US$3800     Corporate User License: US$9500




In comparison with major diseases, the targeting of rare diseases poses many different challenges,
necessitating consideration of bespoke R&D strategies for drug discovery efforts to be successful. This
report examines the role that low disease prevalence plays in determining the most suitable R&D path.

Features and benefits


       Understand the growing interest in developing new treatments for rare diseases, and why low
        patient numbers do not preclude commercial viability.
       Review the regulatory environment governing the development of orphan drugs in different
        countries.
       Identify the key challenges that are presented by low patient prevalences.
       Assess how the research strategy chosen can be influenced by the disease prevalence.
       Compare the scenarios in which repurposing of existing drugs offers advantages over the
        development of novel drugs, and vice versa.

                          http://www.reportsnreports.com/reports/192270-
Buy your copy of this report @
drug-discovery-in-rare-diseases.html

Highlights

Approximately 7,000 rare diseases have been identified, but only a very small proportion of these are
currently well treated. Orphans represent a greater proportion of all new BLAs than they do of NMEs
submitted as NDAs. Most orphan approvals are not first approvals of new drugs but are new orphan
indications for previously approved drugs.

It is possible to obtain orphan drug designation for conditions with a total prevalence greater than that
defined by legislation, but only if medically justifiable subsets can be defined with a lower (overall)
prevalence. Pediatric subsets are most commonly used.

In the development of new treatments for rare diseases it is less critical to seek to optimize the
pharmacokinetic properties of candidates than is the case for common chronic diseases, with parenteral
delivery or frequent oral dosing being much more acceptable provided that efficacy is achieved.
Your key questions answered


       What impact on R&D strategy does disease prevalence have on moving from rare through very
        rare to ultra rare diseases?
       Can more than one drug be a commercial success for treating rare indications, and how do drug
        regulators view the question of drug similarity?
       What are the best ways of identifying patients for recruitment into clinical trials for drugs designed
        to treat rare diseases?
       What are the requirements for a clinical candidate to treat a rare disease?
       What factors determine whether a small-molecule or biologic strategy is most suitable when
        targeting a rare disease?


Explore reports related to Pharmaceutical Market @ http://www.reportsnreports.com/market-
research/pharmaceuticals/

Contact:
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us:

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:25
posted:9/14/2012
language:English
pages:2
Description: ReportsnReports adds a new report "Drug Discovery in Rare Diseases" to its research database.